Non-Hodgkin’s Lymphoma

October 18, 2019

HIV-positive, Non-Hodgkin’s Lymphoma Patients Should Receive Chemotherapy Along with Antiretrovirals Therapy, Retrospective Study Says

News

People with non-Hodgkin’s lymphoma who are HIV-positive and have not received antiretroviral therapy — a treatment that stops HIV from replicating — have similar outcomes on standard R-CHOP chemotherapy, compared ... Read more

October 1, 2019October 1, 2019

Radiation Prior to CAR T-cell Therapy in Non-Hodgkin’s Lymphoma May Ease Side Effects, Study Suggests

News

Treating non-Hodgkin’s lymphoma patients with radiation before giving them CAR T-cell therapy may lessen the likelihood of them experiencing toxic side effects, a small study suggests. This finding was detailed at the ... Read more

September 10, 2019

Biosimilar ABP 798 Shows Similar Safety and Efficacy to Rituxan in Phase 3 Trial for Non-Hodgkin’s Lymphoma

News

ABP 798, a biosimilar to Rituxan (rituximab), is showing comparable efficacy results to its original product in a Phase 3 trial for non-Hodgkin’s lymphoma patients, the treatment’s co-developers, Amgen and Allergan, have ... Read more

August 22, 2019August 22, 2019

Lymphoma Research Foundation to Honor MSK’s Anas Younes at September Gala

News

The Lymphoma Research Foundation will honor Anas Younes, an oncologist and lymphoma expert at Memorial Sloan Kettering (MSK) Cancer Center, with its Distinguished Leadership Award next month at the nonprofit’s annual gala. The ... Read more

August 20, 2019

Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma

News

Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular ... Read more

July 9, 2019

REGN1979 Eliminated Cancer in Most Non-Hodgkin’s Lymphoma Patients in Phase 1 Trial

News

Regeneron‘s bispecific antibody REGN1979 is showing outstanding clinical effectiveness in B-cell non-Hodgkin’s lymphoma patients who received prior treatments, including those who progressed after CAR T-cell therapies. The treatment completely eliminated ... Read more

May 10, 2019May 8, 2019

Famous Lymphoma Survivors Can Be Models for Hope

Columns, Things That Give Me Hope - a Column by Bob McEachern

I don’t like to think about death, much less write about it. Over 11 years as a follicular lymphoma patient, I’ve gotten pretty good at not thinking about it. But ... Read more

May 9, 2019

Sunlight Exposure Reduces Risk of Non-Hodgkin’s Lymphoma, Study Finds

News

People with high exposure to sunlight or ultraviolet radiation are significantly less likely to develop non-Hodgkin’s lymphoma compared to those with low exposure, but vitamin D levels in the body ... Read more

April 12, 2019

Age, Obesity, Comorbidities Linked with Severe Fatigue Among Non-Hodgkin’s Lymphoma Survivors

News

While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, ... Read more

March 21, 2019

PD-L1 Levels, Response to Tecentriq Linked in Younger Cancer Patients

News

Children, adolescents, and young adults with relapsed or refractory cancers — particularly those with lymphoma — have better responses to Genentech‘s immune checkpoint inhibitor Tecentriq (atezolizumab) if they have high ... Read more